{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:01:47Z","timestamp":1791925307914,"version":"4.3.4"},"reference-count":17,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aims to evaluate the drug\u2013drug interaction (DDI) between hetrombopag and cyclosporine in healthy Chinese subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010six eligible subjects enrolled in this single\u2010centre, single\u2010sequence, open\u2010label, DDI study with 3 treatment periods, receiving 5\u2009mg hetrombopag once on Day 1, 100\u2009mg cyclosporine twice daily from Day 11 to Day 15 and 5\u2009mg hetrombopag\u2009+\u2009100\u2009mg cyclosporine on Day 16. Serial blood samples were collected for pharmacokinetic evaluation. Adverse events were monitored throughout the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The plasma hetrombopag geometric mean ratios (90% confidence interval) of maximum plasma concentration, area under the plasma concentration\u2013time curve (AUC) from predose to time of last quantifiable sample and AUC to infinity of coadministration of hetrombopag with cyclosporine <jats:italic>vs<\/jats:italic>. hetrombopag alone were 95.97% (70.08\u2013131.43%), 105.75% (75.04\u2013149.04%) and 104.19% (74.71\u2013145.32%), respectively, indicating multiple doses of cyclosporine had minimal effects on hetrombopag exposure. The geometric mean ratios (90% confidence interval) of maximum blood concentration and AUC at steady state during a dosing interval for blood cyclosporine of coadministration <jats:italic>vs<\/jats:italic>. cyclosporine alone were 100.49% (91.89\u2013109.89%) and 100.81% (107.88\u2013103.82%), respectively, suggesting a single dose of hetrombopag had no impact on the exposure of cyclosporine. Coadministration of hetrombopag with cyclosporine was generally well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No clinically significant DDI was observed when coadministration of hetrombopag with cyclosporine. The results of this study will inform the appropriate use of this combination therapy both in clinical trials and clinical settings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15664","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:12:59Z","timestamp":1674108779000},"page":"2160-2167","source":"Crossref","is-referenced-by-count":3,"title":["A phase I, single\u2010sequence, open\u2010label study to evaluate the drug\u2013drug interaction between hetrombopag and cyclosporine in healthy Chinese subjects"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-2766","authenticated-orcid":false,"given":"Fengshan","family":"Li","sequence":"first","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"},{"name":"Department of Pharmacy\/Evidence\u2010Based Pharmacy Center, West China Second University Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-1949","authenticated-orcid":false,"given":"Hongda","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Jiangsu Hengrui Medicine Co. LTD.  1288 Haike Road, Pudong Shanghai 201210 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyin","family":"Feng","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linrui","family":"Cai","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"},{"name":"Department of Pharmacy\/Evidence\u2010Based Pharmacy Center, West China Second University Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Feng","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Jiangsu Hengrui Medicine Co. LTD.  1288 Haike Road, Pudong Shanghai 201210 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zou","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Jiangsu Hengrui Medicine Co. LTD.  1288 Haike Road, Pudong Shanghai 201210 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Su","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Jiangsu Hengrui Medicine Co. LTD.  1288 Haike Road, Pudong Shanghai 201210 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yu","sequence":"additional","affiliation":[{"name":"National Drug Clinical Trial Institution of West China Second Hospital Sichuan University  Chengdu China"},{"name":"NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation  Chengdu China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children Sichuan University, Ministry of Education  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-017-0511-z"},{"key":"e_1_2_10_3_1","unstructured":"NOVARTIS.FDA approves Novartis drug Promacta\u00ae for first\u2010line SAA and grants breakthrough therapy designation for additional new indication.2018.https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-drug-promacta-first-line-saa-and-grants-breakthrough-therapy-designation-additional-new-indication"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001575\u20101"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12815"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.10.002"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14259"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010385934"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2011.03903.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.130"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"S264","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2021\/22: catalytic receptors","volume":"178","author":"Alexander SP","year":"2021","journal-title":"Br J Pharmacol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15540"},{"key":"e_1_2_10_13_1","unstructured":"US FDA.Drug development and drug interactions|table of substrates inhibitors and inducers.2020.https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table5-2"},{"key":"e_1_2_10_14_1","unstructured":"US FDA.Clinical drug interaction studies \u2014 cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry.https:\/\/www.fda.gov\/media\/134581\/download2020"},{"key":"e_1_2_10_15_1","unstructured":"Novartis Pharmaceuticals Corporation.Neoral (cyclosporine) [package insert]. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050715s027. Revised September 2009. Accessed Dec 09 2022."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.011866"},{"issue":"1","key":"e_1_2_10_17_1","first-page":"1","article-title":"Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017)","volume":"38","author":"Red Blood Cell Disease Group CSoHCMA","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010018\u20103677\u20106"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T03:53:49Z","timestamp":1714449229000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/bcp.15664"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15664","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}